보고
Full briefing
"Barriers to Access and Scale up of Hepatitis C (HCV) Treatment: Gilead’s Anti–Diversion Program, MSF Briefing Document, January 2015"
...MSF has learned that the company will institute an ‘anti-diversion’ programme in developing countries through its distributors and licensees… to prevent what they characterize as the possible ‘bulk diversion’ or re-sale of such medicines… Gilead’s programme violates patient privacy and autonomy...